Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP David Joseph Gaffin sold 2,034 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $34.57, for a total transaction of $70,315.38. Following the completion of the sale, the executive vice president directly owned 233,592 shares in the company, valued at approximately $8,075,275.44. The trade was a 0.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Joseph Gaffin also recently made the following trade(s):
- On Monday, March 2nd, David Joseph Gaffin sold 2,034 shares of Alkermes stock. The shares were sold at an average price of $29.29, for a total transaction of $59,575.86.
Alkermes Trading Down 2.2%
Shares of NASDAQ ALKS opened at $34.08 on Tuesday. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of 23.83, a PEG ratio of 8.69 and a beta of 0.44. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $36.48. The company's 50-day moving average price is $31.44 and its 200 day moving average price is $30.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.29 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.14). Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The business had revenue of $384.55 million during the quarter, compared to analyst estimates of $380.44 million. During the same period in the previous year, the company posted $1.05 earnings per share. Alkermes's revenue was down 10.6% on a year-over-year basis. As a group, research analysts expect that Alkermes plc will post 1.31 earnings per share for the current year.
Institutional Investors Weigh In On Alkermes
Several hedge funds have recently modified their holdings of ALKS. Assetmark Inc. boosted its position in shares of Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company's stock worth $25,000 after acquiring an additional 747 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new stake in shares of Alkermes in the fourth quarter worth approximately $28,000. Johnson Financial Group Inc. acquired a new stake in shares of Alkermes in the third quarter worth approximately $31,000. UMB Bank n.a. boosted its position in shares of Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company's stock worth $34,000 after acquiring an additional 446 shares during the last quarter. Finally, Salomon & Ludwin LLC boosted its position in shares of Alkermes by 115.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company's stock worth $35,000 after acquiring an additional 667 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have issued reports on ALKS. Wolfe Research began coverage on shares of Alkermes in a research note on Monday, February 23rd. They set an "outperform" rating and a $45.00 price target on the stock. Royal Bank Of Canada decreased their price target on shares of Alkermes from $47.00 to $45.00 and set an "outperform" rating on the stock in a research note on Thursday, February 26th. Wells Fargo & Company raised their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Piper Sandler decreased their price target on shares of Alkermes from $45.00 to $43.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 24th. Finally, Wall Street Zen cut shares of Alkermes from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $43.93.
View Our Latest Stock Analysis on ALKS
About Alkermes
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
